Lucid Diagnostics Inc. Common Stock (LUCD)
Stock · NASDAQ · Health Care
$0.991as of 8/28/2026
Price chart
Open in TradingViewActive signals
About LUCD
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 82
- Website
- www.luciddx.com/
Fundamentals
- 1-day range
- $0.972$1.03
- Market cap
- $193.54M
- P/E (trailing)
- —
- P/E (forward)
- -6.31
- EPS (trailing)
- $-0.36
- Dividend yield
- —
- Beta
- 1.17
- Avg. volume
- 1.44M
How Lucid Diagnostics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Lucid Diagnostics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LUCDLucid Diagnostics Inc. Common Stock$0.9989▲ 1.51%Market cap $193.54MP/E —$0.8605$1.63
- EMBCEmbecta Corp. Common Stock$5.05▲ 1.61%Market cap $207.65MP/E 2.59$2.77$15.55
- PDEXPro-Dex Inc. Common Stock$62.37▼ 3.85%Market cap $209.06MP/E 17.93$23.47$69.86
- APYXApyx Medical Corporation Common Stock$3.08▲ 2.67%Market cap $174.35MP/E —$1.7$5.08
- KRMDKORU Medical Systems Inc. Common Stock (DE)$3.24▲ 1.09%Market cap $163.52MP/E —$3.14$6.61
- CVRXCVRx Inc. Common Stock$2.95▼ 3.12%Market cap $157.62MP/E —$2.2$11.3
- STIMNeuronetics Inc. Common Stock$2.95▼ 0.51%Market cap $156.57MP/E —$0.8$3.71
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LUCD Lucid Diagnostics Inc. Common Stock | $193.54M | — | $0.9989 | ▲ 1.51% | $0.8605$1.63 |
| EMBC Embecta Corp. Common Stock | $207.65M | 2.59 | $5.05 | ▲ 1.61% | $2.77$15.55 |
| PDEX Pro-Dex Inc. Common Stock | $209.06M | 17.93 | $62.37 | ▼ 3.85% | $23.47$69.86 |
| APYX Apyx Medical Corporation Common Stock | $174.35M | — | $3.08 | ▲ 2.67% | $1.7$5.08 |
| KRMD KORU Medical Systems Inc. Common Stock (DE) | $163.52M | — | $3.24 | ▲ 1.09% | $3.14$6.61 |
| CVRX CVRx Inc. Common Stock | $157.62M | — | $2.95 | ▼ 3.12% | $2.2$11.3 |
| STIM Neuronetics Inc. Common Stock | $156.57M | — | $2.95 | ▼ 0.51% | $0.8$3.71 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5benzinga · 8/27/2026
- Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5Benzinga · 8/27/2026
- Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst SaysBenzinga · 8/18/2026
- BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price TargetBenzinga · 8/17/2026
- Lucid Diagnostics Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha · 8/13/2026
- Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call TranscriptSeekingAlpha · 8/13/2026
- Lucid Diagnostics Q2 2026 Earnings Call: Complete TranscriptBenzinga · 8/13/2026
- Lucid Diagnostics Q2 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $1.474M Miss $1.943M EstimateBenzinga · 8/13/2026
- Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA TestYahoo · 8/5/2026
Insider Activity
Insider Actions →- Dennis Matheis · May 20, 2026 · Buy245.0K @ $1
Institutional Ownership
March 31, 2026
- Total shares held
- 34.35M
- Total value held
- $39.39M
- Institutional holders
- 98
- Unknown4.64M
- Unknown4.15M
- Unknown4.00M
- Unknown3.64M
- Unknown3.00M
- Unknown2.25M
- Unknown1.58M
- Unknown1.55M
- Unknown1.27M
- Unknown1.13M
See the full, filterable feed with live charts on the MarketWall dashboard.